All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for EISAI, INC. · human health care company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 16, 2026

Official filing document

Bills named in this filing 4

HR 8800
National Defense Authorization Act for Fiscal Year 2027
S 4784
National Defense Authorization Act for Fiscal Year 2027
S 891
Bipartisan Health Care Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Trade (domestic/foreign)

Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.